Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination drug** comprised of estrogens, progesterone, and testosterone, intended to provide replacement for all three major ovarian-derived hormones. Such combinations are primarily used in *hormone replacement therapy (HRT)* for the management of menopausal symptoms, particularly when symptoms are not sufficiently controlled by estrogen and progesterone alone. Estrogens act mainly as agonists at the estrogen receptor, alleviating vasomotor symptoms and preventing bone loss. Progesterone is added to reduce the risk of endometrial hyperplasia and cancer in women with an intact uterus. Testosterone may be included off-label for symptoms such as low libido that persist despite standard HRT, though it is not approved for this use in many regions. There is currently no widely approved or licensed pharmaceutical product that combines all three hormones (estrogens, progesterone, and testosterone) in a single, standardized dosage form for use in hormone replacement therapy[1][2][4]. Instead, custom compounded preparations may be used in clinical practice in select cases, or estrogens and progesterone are used together, and testosterone is added separately[1][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on estrogens + progesterone + testosterone.